UroPrint | Urinary bladder bioprinting for fully autologous transplantation

Summary
A number of conditions, including trauma, inflammation, incontinence, overactive bladder, renal impairments, neurological disorders (like spinal cord injury or spina bifida) and cancer, require bladder augmentation. For almost a century now, the majority of cystoplasties utilize bowel segments (enterocystoplasty). This, almost a century years old, gold standard practice bears numerous risks and complications affecting the majority of patients, thus compromising the quality of life while burdening the health care systems. This has fuelled efforts towards the development of engineered bladder tissue. Advancements in bioprinting technologies are increasingly employed in regenerative medicine but mostly in smaller and less complicated tissues. UroPrint proposes the use of Laser Induced Forward Transfer (LIFT) to generate bladder tissue for autologous transplantation that would meet the biological, mechanical and functional properties of human bladder. To this end, primary urothelial and smooth muscle cells will be obtained from healthy donors and expanded in fully Good Medical Practice compliant methodologies. These will be combined with novel natural autologous scaffold material obtained from platelet lysates. Then, a novel approach in the generation of bladder transplant will be utilized, combining intestine denudation and in vivo printing during surgery using a novel prototype LIFT printer that achieved high spatial resolution (95%) single-urothelial cells.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/964883
Start date: 01-09-2021
End date: 31-08-2025
Total budget - Public funding: 3 058 434,99 Euro - 3 058 434,00 Euro
Cordis data

Original description

A number of conditions, including trauma, inflammation, incontinence, overactive bladder, renal impairments, neurological disorders (like spinal cord injury or spina bifida) and cancer, require bladder augmentation. For almost a century now, the majority of cystoplasties utilize bowel segments (enterocystoplasty). This, almost a century years old, gold standard practice bears numerous risks and complications affecting the majority of patients, thus compromising the quality of life while burdening the health care systems. This has fuelled efforts towards the development of engineered bladder tissue. Advancements in bioprinting technologies are increasingly employed in regenerative medicine but mostly in smaller and less complicated tissues. UroPrint proposes the use of Laser Induced Forward Transfer (LIFT) to generate bladder tissue for autologous transplantation that would meet the biological, mechanical and functional properties of human bladder. To this end, primary urothelial and smooth muscle cells will be obtained from healthy donors and expanded in fully Good Medical Practice compliant methodologies. These will be combined with novel natural autologous scaffold material obtained from platelet lysates. Then, a novel approach in the generation of bladder transplant will be utilized, combining intestine denudation and in vivo printing during surgery using a novel prototype LIFT printer that achieved high spatial resolution (95%) single-urothelial cells.

Status

SIGNED

Call topic

FETOPEN-01-2018-2019-2020

Update Date

27-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.2. EXCELLENT SCIENCE - Future and Emerging Technologies (FET)
H2020-EU.1.2.1. FET Open
H2020-FETOPEN-2018-2020
FETOPEN-01-2018-2019-2020 FET-Open Challenging Current Thinking